The First Phase 3 Win for an mRNA Cancer Therapy Arrives Without Its Numbers
- Merck and Moderna said on 19 August 2026 that Phase 3 INTerpath-001 met its primary endpoint of recurrence-free survival and key secondary endpoint of distant metastasis-free survival at a pre-specified interim analysis. The companies call it the first positive Phase 3 readout for an individualised neoantigen therapy and for an mRNA-based cancer therapy.
- The trial enrolled 1,137 patients with completely resected stage IIB to IV cutaneous melanoma, randomised 2:1 to intismeran autogene at 1 mg every three weeks for up to nine doses plus KEYTRUDA, versus KEYTRUDA alone, for up to roughly 56 weeks. Each therapy encodes up to 34 neoantigens drawn from the individual tumour.
- No hazard ratio, confidence interval, p-value or event count was disclosed for the Phase 3. The release does give the Phase 2b figures from KEYNOTE-942 presented at ASCO 2026: RFS hazard ratio 0.51 (95% CI 0.294 to 0.887) and DMFS hazard ratio 0.411 (95% CI 0.200 to 0.843).
- Safety was consistent with prior reports for the combination with no new signals. The study continues to evaluate overall survival and other secondary endpoints. Data go to an international medical meeting, with regulatory filing discussions to follow. The INTerpath programme now spans nine Phase 2 and Phase 3 trials across melanoma, NSCLC, bladder and renal cell carcinoma.
Clinical read
The headline is correct and historic. The number that determines what it is worth was not published. Statistical significance at a pre-specified interim tells you the direction of effect. It does not tell you the size, and size is the entire commercial question.
- The Phase 2b anchor is high and statistically fragile. KEYNOTE-942 returned an RFS hazard ratio of 0.51 with a confidence interval running to 0.887, and a DMFS interval running to 0.843. Those are wide because the trial was small. At 1,137 patients expect a tighter and very likely less dramatic estimate.
- An interim readout captures recurrences, not survival. Melanoma recurrences cluster in the first 2 years after resection, so an interim analysis catches most of them while overall survival stays open for years. Adjuvant melanoma has a long history of recurrence benefit arriving well ahead of any survival signal.
- The programme is the asset, and manufacturing is the constraint nobody has priced. Nine trials now run across four tumour types, each dose built from a single patient’s tumour and encoding up to 34 neoantigens. Ask about turnaround time from resection to first dose before modelling any launch curve.
Read the original source (Merck and Moderna) →
GeographyGlobal